A PHASE 2/3 MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLINATUMOMAB IN SUBJECTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA
- Registry ID
- 20150292
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2017-08-31
- Completion date
- 2017-12-21
- Last update
- 2016-08-19
Conditions
- B-CELL NON-HODGKIN'S LYMPHOMA
Related clinical trials
- A PHASE 1/2 OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF GSK5926371 IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
- A MODULAR PHASE II, SINGLE-ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD0486 IN PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (SOUNDTRACK-B)
- A PHASE 1B MULTICENTER, OPEN-LABEL, STUDY OF JNJ-90014496, AN AUTOLOGOUS CD19/CD20
BI-SPECIFIC CAR-T CELL THERAPY IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL
NON-HODGKIN LYMPHOMA
- A PHASE I COHORT DOSE ESCALATION AND EXPANSION TRIAL TO DETERMINE THE SAFETY, TOLERANCE, MAXIMUM TOLERATED DOSE, AND PRELIMINARY ANTINEOPLASTIC ACTIVITY OF IKS03, A CD19-TARGETING ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH ADVANCED B CELL NON-HODGKIN LYMPHOMAS (NHL)
- A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
View on source registry